The Charles T. Campbell Eye Microbiology Lab
UPMCUniversity of Pittsburgh Schools of the Health Sciences
HomeContact InformationLab Diagnostic TestingAntibiotic SusceptibilityAntimicrobial TherapyCurrent ResearchPhotos

Ocular Microbiology and Immunology Group
Back to OMIG Main Page

2012 Agenda and Abstracts | < Previous | Next >

2012 OMIG Abstract 18

The Pharmacokinetics of Voriconazole 1% Eye Drops
E. Chan4, D. Al-Badriyeh1,2, C.F. Neoh2,7, L. Leung3, R. O. Fullinfaw5, V. Jhanji4, R.B. Vajpayee4,
G.E. Davies5, K. Stewart2 and D.C.M. Kong2
1College of Pharmacy, Qatar University, Doha, Qatar; 2Centre for Medicine Use and Safety, Monash University, Australia; 3Pharmacy Department, Royal Victorian Eye and Ear Hospital, Australia; 4Corneal Unit, Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, Australia; 5Special Chemistry, Royal Melbourne Hospital, Australia; 6Defence Materiel Organisation, Southbank, Australia; 7Faculty of Pharmacy, University of Technology Mara, Penang, Malaysia

Purpose: To evaluate the change in concentration of voriconazole in the aqueous over time after topical administration of voriconazole 1% eye drops.

Methods: Eligible patients attending the Royal Victorian Eye and Ear Hospital for elective cataract surgery between 2009 and 2011 were invited to participate in the study. Participants received 1 drop (~50uL) of voriconazole 1% eye drops prior to the scheduled surgery. During surgery, aqueous was removed and analysed to determine the concentration of voriconazole. Samples were taken at 20±5, 40±5, 60±5 and 80±5 minutes after voriconazole instillation.  

Results: Five participants provided aqueous samples at each of the four sampling points. The median voriconazole concentrations in the aqueous were 3.2 (range 1.1-4.1), 3.1 (2.1-3.4), 1.9 (1.2-5.1) and 2.0 (0.9-2.3) mg/L respectively, at 20, 40, 60 and 80 minutes after voriconazole instillation.

Conclusion: The voriconazole concentrations achieved in the aqueous for the first 80 min after topical administration were consistently higher than the in vitro MIC90 of voriconazole against typical keratitis-causative fungi. The data suggest that reducing the frequency of administration of voriconazole eye drops therapy may be adequate to manage most fungal keratitis.

Disclosure: None pertaining to current study. Financial support has been received for unrelated studies by EC (Allergan) and DCMK (Pfizer, Merck, Gilead Sciences).

2012 Agenda and Abstracts | < Previous | Next >